Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
The Lancet. Haematology|November 5, 2025
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 studyRuben Mesa, Harinder Gill, Lei Zhang, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Nature Communications|May 8, 2021
Co-evolution of tumor and immune cells during progression of multiple myelomaRuiyang Liu, Qingsong Gao, Steven M Foltz, et al.
Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Blood|August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosisAyalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Cancer Research Communications|March 27, 2023
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq AnalysisLijun Yao, Reyka G Jayasinghe, Brian H Lee, et al.
Blood Advances|January 28, 2026
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER studyJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The New England Journal of Medicine|December 14, 2016
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesJohn S Welch, Allegra A Petti, Christopher A Miller, et al.
NEJM Evidence|February 6, 2024
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
Cancer Discovery|April 17, 2026
Spatial Mapping of the Precancer-to-Cancer Transition in Breast and ProstateErik Storrs, Chia-Kuei Mo, Wen-Hung Chou, et al.
Pageof 10